ADURIBEQ Trademark

Trademark Overview

On Thursday, March 5, 2020, a trademark application was filed for ADURIBEQ with the United States Patent and Trademark Office. The USPTO has given the ADURIBEQ trademark a serial number of 88822054. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 21, 2024. This trademark is owned by Celgene Corporation. The ADURIBEQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
aduribeq

General Information

Serial Number88822054
Word MarkADURIBEQ
Filing DateThursday, March 5, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 20, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 11, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Monday, March 9, 2020NEW APPLICATION ENTERED
Wednesday, March 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 26, 2020ASSIGNED TO EXAMINER
Friday, May 29, 2020NON-FINAL ACTION WRITTEN
Friday, May 29, 2020NON-FINAL ACTION E-MAILED
Friday, May 29, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 23, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 23, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 24, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 11, 2020FINAL REFUSAL WRITTEN
Friday, December 11, 2020FINAL REFUSAL E-MAILED
Friday, December 11, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, June 10, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, June 10, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 11, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 30, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 20, 2021PUBLISHED FOR OPPOSITION
Tuesday, July 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 23, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, February 23, 2022SOU EXTENSION 1 FILED
Wednesday, February 23, 2022SOU EXTENSION 1 GRANTED
Friday, February 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 23, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 23, 2022SOU EXTENSION 2 FILED
Tuesday, August 23, 2022SOU EXTENSION 2 GRANTED
Thursday, August 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, March 13, 2023SOU EXTENSION 3 FILED
Monday, March 13, 2023SOU EXTENSION 3 GRANTED
Wednesday, March 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 29, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 29, 2023SOU EXTENSION 4 FILED
Tuesday, August 29, 2023SOU EXTENSION 4 GRANTED
Thursday, August 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 7, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 7, 2024SOU EXTENSION 5 FILED
Friday, February 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 23, 2024SOU EXTENSION 5 GRANTED
Saturday, February 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 21, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, October 21, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

aduribeq diseases pharmaceutical human preparations disorders cancer immune namely anti system